ER 50891

ER 50891 is a RARα antagonist. ER 50891 can significantly antagonize the inhibitory effect of all-trans retinoic acid (ATRA) on the total cell metabolic activity and proliferation of MC3T3-E1 preosteoblasts. ER 50891 rescues ATRA-inhibited osteocalcin (OCN) expression and extracellular matrix mineralization, and suppresses alkaline phosphatase (ALP) activity synergistically. ER 50891 can be used for the study of osteoporosis related to ATRA-induced inhibition of osteoblastogenesis[1].

Product Specifications

CAS Number

[187400-85-7]

UNSPSC

12352005

Target

RAR/RXR

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/er-50891.html

Purity

99.86

Solubility

10 mM in DMSO

Smiles

O=C(O)C1=CC=C(C2=CC=C(C3=NC4=C(C(C)C)C=CC=C4C(C5=CC=CC=C5)=C3)N2)C=C1

Molecular Formula

C29H24N2O2

Molecular Weight

432.51

References & Citations

[1]Wang S, et al. The Antagonist of Retinoic Acid Receptor α, ER-50891 Antagonizes the Inhibitive Effect of All-Trans Retinoic Acid and Rescues Bone Morphogenetic Protein 2-Induced Osteoblastogenic Differentiation. Drug Des Devel Ther. 2020 Jan 22;14:297-308.